Cabaletta Bio Reports Favorable Early Clinical Data for Rese-cel in Autoimmune Conditions

Cabaletta Bio presented positive Phase 1/2 clinical data for rese-cel, a targeted cell therapy for autoimmune diseases, at ACR Convergence 2026. The findings indicated immunomodulator-free durability and a favorable benefit-risk profile across patients with dermatomyositis, systemic sclerosis, lupus, and myasthenia gravis, suggesting potential for this novel treatment approach.